{"id":"https://openalex.org/W2947445708","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2005","title":"Efficacy and safety of selinexor in recurrent glioblastoma.","display_name":"Efficacy and safety of selinexor in recurrent glioblastoma.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2947445708","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2005","mag":"2947445708"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.2005","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057541817","display_name":"Andrew B. Lassman","orcid":"https://orcid.org/0000-0001-7386-9928","observed_orcids":["https://orcid.org/0000-0001-7386-9928"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew B. Lassman","raw_affiliation_strings":["Columbia University Irving Medical Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University Irving Medical Center, New York, NY;","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021656597","display_name":"Patrick Yung Wen","orcid":"https://orcid.org/0000-0002-0774-7700","observed_orcids":["https://orcid.org/0000-0002-0774-7700","https://orcid.org/0000-0003-3224-3042","https://orcid.org/0000-0002-2452-0540"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210161994","display_name":"Dana-Farber Brigham Cancer Center","ror":"https://ror.org/05rgrbr06","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I4210117453","https://openalex.org/I4210161994","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Y. Wen","raw_affiliation_strings":["Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210161994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010891460","display_name":"Martin J. van den Bent","orcid":"https://orcid.org/0000-0001-5710-5127","observed_orcids":["https://orcid.org/0000-0001-5710-5127"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I4210149908","display_name":"Erasmus MC Cancer Institute","ror":"https://ror.org/03r4m3349","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686","https://openalex.org/I4210149908"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Martin J. Van Den Bent","raw_affiliation_strings":["Erasmus MC Cancer Center, Rotterdam, Netherlands;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC Cancer Center, Rotterdam, Netherlands;","institution_ids":["https://openalex.org/I2801952686","https://openalex.org/I4210149908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059797681","display_name":"Scott Randall Plotkin","orcid":"https://orcid.org/0000-0002-6109-6419","observed_orcids":["https://orcid.org/0000-0002-6109-6419"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Randall Plotkin","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001268928","display_name":"Annemiek Walenkamp","orcid":"https://orcid.org/0000-0003-4958-8960","observed_orcids":["https://orcid.org/0000-0003-4958-8960"]},"institutions":[{"id":"https://openalex.org/I1334415907","display_name":"University Medical Center Groningen","ror":"https://ror.org/03cv38k47","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I1334415907"]},{"id":"https://openalex.org/I169381384","display_name":"University of Groningen","ror":"https://ror.org/012p63287","country_code":"NL","type":"education","lineage":["https://openalex.org/I169381384"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Anna Maria Elisabeth Walenkamp","raw_affiliation_strings":["Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands;","institution_ids":["https://openalex.org/I1334415907","https://openalex.org/I169381384"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112537228","display_name":"Xiu Ying Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiu Huang","raw_affiliation_strings":["Karyopharm Therapeutics Inc, Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics Inc, Newton, MA;","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052640144","display_name":"Karla Rodriguez-Lopez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karla Rodriguez-Lopez","raw_affiliation_strings":["Karyopharm Therapeutics Inc, Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics Inc, Newton, MA;","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112906141","display_name":"Michael G. Kauffman","orcid":"https://orcid.org/0000-0001-5643-0200","observed_orcids":["https://orcid.org/0000-0001-5643-0200"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael G. Kauffman","raw_affiliation_strings":["Karyopharm Therapeutics Inc., Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics Inc., Newton, MA;","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051352882","display_name":"Sharon Shacham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Shacham","raw_affiliation_strings":["Karyopharm Therapeutics Inc., Newton, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karyopharm Therapeutics Inc., Newton, MA;","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070373312","display_name":"Morten Mau\u2010S\u00f8rensen","orcid":"https://orcid.org/0000-0003-2235-1250","observed_orcids":["https://orcid.org/0000-0003-2235-1250"]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Morten Mau-S\u00f8rensen","raw_affiliation_strings":["Rigshospitalet, Copenhagen, Denmark;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rigshospitalet, Copenhagen, Denmark;","institution_ids":["https://openalex.org/I2802709434"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"2005","last_page":"2005"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/selinexor","display_name":"selinexor","score":0.925000011920929},{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9909999966621399},{"id":"https://openalex.org/keywords/selective-inhibitor-of-nuclear-export","display_name":"selective inhibitor of nuclear export","score":0.9229999780654907},{"id":"https://openalex.org/keywords/oral-chemotherapy","display_name":"oral chemotherapy","score":0.3440000116825104},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9200000166893005},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.42100000381469727},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5849999785423279},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.628000020980835},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.4790000021457672},{"id":"https://openalex.org/keywords/p27","display_name":"p27","score":0.9160000085830688}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8594844937324524},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.708372950553894},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3508343994617462},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3075793981552124}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.2005","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.2005","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.2005","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2972238855","https://openalex.org/W3209190780","https://openalex.org/W3111333338","https://openalex.org/W4231239683","https://openalex.org/W3169669455","https://openalex.org/W3112470837","https://openalex.org/W2609816641","https://openalex.org/W3215508843","https://openalex.org/W4404236967","https://openalex.org/W3029248227"],"abstract_inverted_index":{"2005":[0],"Background:":[1],"New":[2],"treatment":[3,125],"modalities":[4],"are":[5],"needed":[6],"for":[7,89,299],"recurrent":[8],"glioblastoma":[9],"(rGBM).":[10],"Selinexor":[11],"(SEL)":[12],"is":[13,74,297],"a":[14,51,291],"novel,":[15],"oral":[16],"selective":[17],"inhibitor":[18],"of":[19,26,64,81,98,156,170,180,233,293],"nuclear":[20,24],"export":[21],"which":[22],"forces":[23],"retention":[25],"tumor":[27],"suppressor":[28],"proteins":[29],"including":[30],"p53":[31],"and":[32,46,115,128,132,226,266,276,286],"p27,":[33],"leading":[34],"to":[35,66],"apoptosis.":[36],"We":[37,57],"previously":[38],"reported":[39],"interim":[40],"results":[41,61],"showing":[42],"tolerability,":[43],"preliminary":[44],"efficacy,":[45,272],"blood-brain":[47],"barrier":[48],"penetration":[49],"in":[50,96,244,279,302],"surgical":[52],"cohort":[53],"(N":[54,69],"=":[55,70],"8).":[56],"now":[58],"report":[59],"updated":[60],"following":[62],"completion":[63],"accrual":[65],"non-surgical":[67],"cohorts":[68],"68).":[71],"Methods:":[72],"This":[73],"an":[75],"open-label,":[76],"multicenter,":[77],"phase":[78],"2":[79,174,220],"study":[80],"SEL":[82,270,289],"monotherapy.":[83],"Patients":[84],"(pts)":[85],"not":[86],"undergoing":[87],"surgery":[88],"measurable":[90],"rGBM":[91],"(per":[92],"RANO)":[93],"were":[94,110,159,190,254],"enrolled":[95],"one":[97],"3":[99],"arms":[100],"encompassing":[101],"different":[102],"dosing":[103],"schedules.":[104],"Treatment":[105],"was":[106,117,130,135,140,163,173,201,235],"continuous,":[107],"although":[108],"cycles":[109],"defined":[111],"as":[112],"28":[113],"days":[114],"response":[116,234],"assessed":[118],"every":[119],"other":[120],"cycle":[121],"by":[122,148],"MRI.":[123],"Prior":[124],"with":[126,228,273],"radiotherapy":[127],"temozolomide":[129],"required":[131],"prior":[133,171],"bevacizumab":[134],"exclusionary.":[136],"The":[137,194,238],"primary":[138],"endpoint":[139],"6-month":[141],"progression":[142],"free":[143,191],"survival":[144],"(6mPFS)":[145],"rate,":[146],"calculated":[147],"the":[149,178,181,283],"Kaplan":[150],"Meier":[151],"method.":[152],"Results:":[153],"A":[154],"total":[155],"76":[157],"pts":[158,211,245],"enrolled.":[160],"Median":[161,168,231],"age":[162],"56":[164],"years":[165],"(range":[166,175],"21-78).":[167],"number":[169],"treatments":[172],"1-7).":[176],"At":[177],"end":[179],"6":[182],"cycles,":[183],"30.2%":[184],"patients":[185],"on":[186,197,212,246,282],"80":[187,198,213,294],"mg":[188,199,214,248,250,252,295],"QW":[189,200,215,253,296],"from":[192],"progression.":[193],"6mPFS":[195],"rate":[196],"15.1%.":[202],"Best":[203],"RANO-defined":[204],"responses":[205,275],"(assessed":[206],"locally)":[207],"among":[208],"26":[209],"evaluable":[210],"included":[216],"1":[217],"complete":[218],"response,":[219],"partial":[221],"responses,":[222],"7":[223],"stable":[224],"disease,":[225],"16":[227],"progressive":[229],"disease.":[230],"duration":[232],"10.8":[236],"months.":[237],"most":[239],"common":[240],"related":[241],"adverse":[242],"events":[243],"~85":[247],"BIW/60":[249],"BIW/80":[251],"nausea":[255],"(42%/64%/60%),":[256],"leukopenia":[257],"(38%/7%/43%),":[258],"fatigue":[259],"(71%/71%/43%),":[260],"neutropenia":[261],"(29%/14%/33%),":[262],"decreased":[263],"appetite":[264],"(46%/71%/27%),":[265],"thrombocytopenia":[267],"(67%/29%/23%).":[268],"Conclusions:":[269],"demonstrated":[271],"durable":[274],"disease":[277],"stabilization":[278],"rGBM.":[280,303],"Based":[281],"favorable":[284],"efficacy":[285],"safety":[287],"profile,":[288],"at":[290],"dose":[292],"recommended":[298],"further":[300],"development":[301],"Clinical":[304],"trial":[305],"information:":[306],"NCT01986348.":[307],"[Table:":[308],"see":[309],"text]":[310]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-06-07T00:00:00"}